{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:16:42Z","timestamp":1773195402542,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T00:00:00Z","timestamp":1420761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s13277-014-3006-6","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T01:43:08Z","timestamp":1420681388000},"page":"3679-3684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["IL-6 polymorphism in non-small cell lung cancer: a prognostic value?"],"prefix":"10.1007","volume":"36","author":[{"given":"M\u00f3nica","family":"Gomes","sequence":"first","affiliation":[]},{"given":"Ana","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Catarino","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"issue":"2","key":"3006_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3006_CR2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3006_CR3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"3006_CR4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1634\/theoncologist.12-2-201","volume":"12","author":"A Araujo","year":"2007","unstructured":"Araujo A et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer\u2014a review of the literature. Oncologist. 2007;12(2):201\u201310.","journal-title":"Oncologist"},{"issue":"6917","key":"3006_CR5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860\u20137.","journal-title":"Nature"},{"issue":"5","key":"3006_CR6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI31537","volume":"117","author":"WW Lin","year":"2007","unstructured":"Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175\u201383.","journal-title":"J Clin Invest"},{"issue":"2","key":"3006_CR7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1078-0432.CCR-08-0149","volume":"15","author":"BB Aggarwal","year":"2009","unstructured":"Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425\u201330.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"3006_CR8","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3747\/co.19.1058","volume":"19","author":"GD Brandao","year":"2012","unstructured":"Brandao GD, Brega EF, Spatz A. The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol. 2012;19 Suppl 1:S24\u201332.","journal-title":"Curr Oncol"},{"issue":"1","key":"3006_CR9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2009.11.017","volume":"50","author":"M Crohns","year":"2010","unstructured":"Crohns M et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy\u2014association of interleukin-8 and VEGF with survival. Cytokine. 2010;50(1):30\u20136.","journal-title":"Cytokine"},{"issue":"7","key":"3006_CR10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2010.02.026","volume":"46","author":"T Ara","year":"2010","unstructured":"Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46(7):1223\u201331.","journal-title":"Eur J Cancer"},{"issue":"Suppl 3","key":"3006_CR11","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","volume":"4","author":"T Naka","year":"2002","unstructured":"Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4 Suppl 3:S233\u201342.","journal-title":"Arthritis Res"},{"issue":"5-6","key":"3006_CR12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.20452\/pamw.144","volume":"117","author":"M Lukaszewicz","year":"2007","unstructured":"Lukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117(5-6):247\u201351.","journal-title":"Pol Arch Med Wewn"},{"issue":"6","key":"3006_CR13","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/S0002-9440(10)63067-2","volume":"159","author":"D Giri","year":"2001","unstructured":"Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001;159(6):2159\u201365.","journal-title":"Am J Pathol"},{"issue":"3","key":"3006_CR14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcb.20477","volume":"95","author":"Z Culig","year":"2005","unstructured":"Culig Z et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95(3):497\u2013505.","journal-title":"J Cell Biochem"},{"issue":"16","key":"3006_CR15","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3748\/wjg.v19.i16.2449","volume":"19","author":"L Giannitrapani","year":"2013","unstructured":"Giannitrapani L et al. Genetic association of interleukin-6 polymorphism (-174G\/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol. 2013;19(16):2449\u201355.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"3006_CR16","first-page":"3066","volume":"63","author":"LA Hefler","year":"2003","unstructured":"Hefler LA et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63(12):3066\u20138.","journal-title":"Cancer Res"},{"issue":"11","key":"3006_CR17","first-page":"4497","volume":"29","author":"X Zhang","year":"2009","unstructured":"Zhang X et al. IL-6 regulates MMP-10 expression via JAK2\/STAT3 signaling pathway in a human lung adenocarcinoma cell line. Anticancer Res. 2009;29(11):4497\u2013501.","journal-title":"Anticancer Res"},{"issue":"62","key":"3006_CR18","first-page":"16535","volume":"9","author":"P Zarogoulidis","year":"2013","unstructured":"Zarogoulidis P et al. Interleukin-6 cytokine: a multifunctional glycoprotein for cancer. Immunol Res. 2013;9(62):16535.","journal-title":"Immunol Res"},{"issue":"4","key":"3006_CR19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3892\/etm.2012.454","volume":"3","author":"RY Liu","year":"2012","unstructured":"Liu RY et al. Association between IL6\u2013174G\/C and cancer: a meta-analysis of 105,482 individuals. Exp Ther Med. 2012;3(4):655\u201364.","journal-title":"Exp Ther Med"},{"issue":"4\u20135","key":"3006_CR20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","volume":"13","author":"K Ishihara","year":"2002","unstructured":"Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4\u20135):357\u201368.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"14","key":"3006_CR21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/jnci\/djr216","volume":"103","author":"SR Pine","year":"2011","unstructured":"Pine SR et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103(14):1112\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"3006_CR22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5306\/wjco.v2.i12.384","volume":"2","author":"A Azevedo","year":"2011","unstructured":"Azevedo A et al. IL-6\/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011;2(12):384\u201396.","journal-title":"World J Clin Oncol"},{"issue":"4","key":"3006_CR23","first-page":"413","volume":"17","author":"F Vita De","year":"1998","unstructured":"De Vita F et al. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res. 1998;17(4):413\u20137.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2\u20133","key":"3006_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1744-313X.1998.tb01147.x","volume":"25","author":"O Olomolaiye","year":"1998","unstructured":"Olomolaiye O, Wood NA, Bidwell JL. A novel NlaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet. 1998;25(2\u20133):267.","journal-title":"Eur J Immunogenet"},{"issue":"7","key":"3006_CR25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI2629","volume":"102","author":"D Fishman","year":"1998","unstructured":"Fishman D et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Investig. 1998;102(7):1369\u201376.","journal-title":"J Clin Investig"},{"issue":"1","key":"3006_CR26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4238\/2014.January.10.5","volume":"13","author":"S Mandal","year":"2014","unstructured":"Mandal S, Abebe F, Chaudhary J. 174G\/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet Mol Res. 2014;13(1):139\u201351.","journal-title":"Genet Mol Res"},{"issue":"4","key":"3006_CR27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/00007890-200108270-00027","volume":"72","author":"ED Cox","year":"2001","unstructured":"Cox ED et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation. 2001;72(4):720\u20136.","journal-title":"Transplantation"},{"issue":"11","key":"3006_CR28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0198-8859(02)00440-8","volume":"63","author":"A Meenagh","year":"2002","unstructured":"Meenagh A et al. Frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East and South America. Hum Immunol. 2002;63(11):1055\u201361.","journal-title":"Hum Immunol"},{"issue":"6","key":"3006_CR29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"3006_CR30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ntr\/ntp010","volume":"11","author":"CG Husten","year":"2009","unstructured":"Husten CG. How should we define light or intermittent smoking? Does it matter? Nicotine Tob Res. 2009;11(2):111\u201321.","journal-title":"Nicotine Tob Res"},{"issue":"10","key":"3006_CR31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/hmg\/ddg132","volume":"12","author":"OP Kristiansen","year":"2003","unstructured":"Kristiansen OP et al. Association of a functional 17beta-estradiol sensitive IL6-174G\/C promoter polymorphism with early-onset type 1 diabetes in females. Hum Mol Genet. 2003;12(10):1101\u201310.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"3006_CR32","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/ijc.23173","volume":"121","author":"SP Hussain","year":"2007","unstructured":"Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373\u201380.","journal-title":"Int J Cancer"},{"issue":"5","key":"3006_CR33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3892\/br.2014.300","volume":"2","author":"M Yang","year":"2014","unstructured":"Yang M, Li C, Li M. Association of interleukin-6 (-174G\/C) polymorphism with the prostate cancer risk: a meta-analysis. Biomed Rep. 2014;2(5):637\u201343.","journal-title":"Biomed Rep"},{"issue":"8","key":"3006_CR34","doi-asserted-by":"crossref","first-page":"e43075","DOI":"10.1371\/journal.pone.0043075","volume":"7","author":"B Zhou","year":"2012","unstructured":"Zhou B et al. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS ONE. 2012;7(8):e43075.","journal-title":"PLoS ONE"},{"issue":"5","key":"3006_CR35","first-page":"1773","volume":"30","author":"E Wojcik","year":"2010","unstructured":"Wojcik E et al. IL-6 and VEGF in small cell lung cancer patients. Anticancer Res. 2010;30(5):1773\u20138.","journal-title":"Anticancer Res"},{"issue":"1","key":"3006_CR36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/0008-5472.CAN-08-0613","volume":"69","author":"T Ara","year":"2009","unstructured":"Ara T et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009;69(1):329\u201337.","journal-title":"Cancer Res"},{"issue":"5","key":"3006_CR37","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","volume":"159","author":"A Ogata","year":"1997","unstructured":"Ogata A et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159(5):2212\u201321.","journal-title":"J Immunol"},{"issue":"1","key":"3006_CR38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1359-6101(00)00021-6","volume":"12","author":"PC Smith","year":"2001","unstructured":"Smith PC et al. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12(1):33\u201340.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"3006_CR39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2009.01.002","volume":"15","author":"J Bollrath","year":"2009","unstructured":"Bollrath J et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009;15(2):91\u2013102.","journal-title":"Cancer Cell"},{"issue":"46","key":"3006_CR40","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","volume":"21","author":"G Niu","year":"2002","unstructured":"Niu G et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002;21(46):7001\u201310.","journal-title":"Oncogene"},{"issue":"5","key":"3006_CR41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)64278-2","volume":"162","author":"L Quintanilla-Martinez","year":"2003","unstructured":"Quintanilla-Martinez L et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol. 2003;162(5):1449\u201361.","journal-title":"Am J Pathol"},{"issue":"12","key":"3006_CR42","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","volume":"117","author":"SP Gao","year":"2007","unstructured":"Gao SP et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007;117(12):3846\u201356.","journal-title":"J Clin Invest"},{"issue":"7","key":"3006_CR43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim MY et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315\u201326.","journal-title":"Cell"},{"issue":"8","key":"3006_CR44","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.7314\/APJCP.2013.14.8.4765","volume":"14","author":"XY Song","year":"2013","unstructured":"Song XY et al. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14(8):4765\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3006_CR45","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/1471-2407-14-759","volume":"14","author":"A Markkula","year":"2014","unstructured":"Markkula A et al. IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort. BMC Cancer. 2014;14:759.","journal-title":"BMC Cancer"},{"issue":"2","key":"3006_CR46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/01.ju.0000168723.42824.40","volume":"174","author":"D Tan","year":"2005","unstructured":"Tan D et al. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol. 2005;174(2):753\u20136.","journal-title":"J Urol"},{"issue":"3","key":"3006_CR47","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10620-008-0390-z","volume":"54","author":"R Talar-Wojnarowska","year":"2009","unstructured":"Talar-Wojnarowska R et al. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2009;54(3):683\u20139.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"3006_CR48","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2006.08.043","volume":"103","author":"R Garg","year":"2006","unstructured":"Garg R et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103(3):793\u20136.","journal-title":"Gynecol Oncol"},{"issue":"20","key":"3006_CR49","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.3760\/cma.j.issn.0366-6999.20130578","volume":"126","author":"YS Wang","year":"2013","unstructured":"Wang YS et al. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment. Chin Med J (Engl). 2013;126(20):3931\u20135.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3006_CR50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1055-9965.EPI-08-0705","volume":"18","author":"L Enewold","year":"2009","unstructured":"Enewold L et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009;18(1):215\u201322.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"3006_CR51","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.27892","volume":"132","author":"CH Chang","year":"2013","unstructured":"Chang CH et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer. 2013;132(9):1977\u201385.","journal-title":"Int J Cancer"},{"issue":"22","key":"3006_CR52","first-page":"8051","volume":"63","author":"A DeMichele","year":"2003","unstructured":"DeMichele A et al. Interleukin-6\u2013174G\u2013\u2009>\u2009C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003;63(22):8051\u20136.","journal-title":"Cancer Res"},{"issue":"12","key":"3006_CR53","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/bjc.2014.540","volume":"111","author":"SA Patel","year":"2014","unstructured":"Patel SA et al. Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. Br J Cancer. 2014;111(12):2287\u201396.","journal-title":"Br J Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-3006-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-3006-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-3006-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:33:51Z","timestamp":1747402431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-3006-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-3006-6","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,9]]}}}